News BioNTech SE Börse Stuttgart

Equities

22UA

US09075V1026

Market Closed - Börse Stuttgart Other stock markets 13:26:13 2024-05-03 EDT			5-day change	1st Jan Change
85.95 ^EUR	+0.35%		+4.63%	-3.17%

05-01	European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	MT
04-25	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech For Infringing MRNA Vaccine Patents	05-03	AQ
BioNTech : Joint report of the Management Board of BioNTech SE and the management of BioNTech Collaborations GmbH on the domination and profit and loss transfer agreement pursuant to Section 293a AktG	05-02	PU
BioNTech : Report of the Management Board on Agenda Items 12 and 13 lit. c) and d)	05-02	PU
BioNTech : Extracts from the minutes of the Annual General Meetings of 18 August 2017, 19 August 2019, 26 June 2020 and 22 June 2021 (2017/2019 share option program and 2021 share option program)	05-02	PU
BioNTech : Report of the Management Board on Agenda Items 12 and 13 lit. c) and d)	05-02	PU
BioNTech : Report of the Management Board on Agenda Item 13	05-02	PU
BioNTech : Extracts from the minutes of the Annual General Meetings of 18 August 2017, 19 August 2019, 26 June 2020 and 22 June 2021 (2017/2019 share option program and 2021 share option program)	05-02	PU
BioNTech : Draft of the domination and profit and loss transfer agreement between BioNTech SE and BioNTech Collaborations GmbH	05-02	PU
BioNTech : Annual financial statements of BioNTech SE as of 31 December 2022	05-02	PU
BioNTech : Annual Report 2022 with the Consolidated Financial Statements as of 31 December 2022, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2022 financial year	05-02	PU
BioNTech : Annual financial statements of BioNTech SE as of 31 December 2023	05-02	PU
BioNTech : Opening balance sheet of BioNTech Collaborations GmbH as of 18 March 2024	05-02	PU
BioNTech : Registration and authorization form as well as authorization and instruction form	05-02	PU
BioNTech : Invitation to the 2024 Annual General Meeting	05-02	PU
BioNTech : Information pursuant to Section 125 AktG in conjunction with Article 4 (1) and Table 3 of Implementing Regulation (EU) 2018/1212	05-02	PU
BioNTech : Annual Report 2023 with the Consolidated Financial Statements as of 31 December 2023, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2023 financial year	05-02	PU
BioNTech : Annual Financial Statements as of 31 December 2023	05-02	PU
BioNTech : Proposal of the Management Board for the appropriation of the balance sheet profit for the 2023 financial year	05-02	PU
BioNTech : Compensation Report for the 2023 financial year	05-02	PU
BioNTech : Compensation system 2024 for the members of the Management Board of BioNTech SE	05-02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am